# A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

Source: https://onco.cc/trials/nct06974929/  
OnCo record `nct06974929` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HRS-6209 Capsules in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer is a phase 1/2 interventional study registered as NCT06974929 by Jiangsu HengRui Medicine Co., Ltd., with 80 participants planned, started 2025-05-22 and due to reach its primary completion in 2026-12. Interventions recorded: HRS-6209 Capsules, Letrozole Tablets and HRS-2189 Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06974929
- Phase: 1/2
- Setting: An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 Combination Therapy in Patients With Breast Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06974929: https://clinicaltrials.gov/study/NCT06974929

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06974929.json